Efficacy and Safety of Canakinumab in sJIA Patients with and without Fever at Baseline: Results from an Open-label, Active Treatment Extension Study

Psoriatic Arthritis

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

Rheumatol Ther.

Nash P, Coates LC, Kivitz AJ, Mease PJ, Gladman DD, Covarrubias-Cobos JA, FitzGerald O, Fleishaker D, Wang C, Wu J, Hsu MA, Menon S, Fallon L, Romero AB, Kanik KS

doi: 10.1007/s40744-020-00209-4.

Atopic Dermatitis

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Br J Dermatol

Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP, Kamal MA, O'Malley JT, Patel N, Graham NMH, Bansal A

doi: 10.1111/bjd.19460

Rheumatoid Arthritis

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis

Arthritis Res Ther.

Cohen S, Pablos JL, Pavelka K, Müller GA, Matsumoto A, Kivitz A, Wang H, Krishnan E

doi: 10.1186/s13075-019-1857-3.

Rheumatoid Arthritis

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Arthritis Res Ther.

Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, Mojcik C, DeMasi R, Strengholt S, Kwok K, Lazariciu I, Wang L, Cohen S

doi: 10.1186/s13075-019-1866-2.

COMMENTED

Psoriatic Arthritis

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

★ 3 Recommended and commented by Dr Heino Prillwitz, Faculty Member

Ann Rheum Dis.

Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS, SPIRIT H2H study group.

doi: 10.1136/annrheumdis-2019-215386.

Further Publications Dermatology

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

Lancet Neurol

Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T, patisiran Global OLE study group.

doi: 10.1016/S1474-4422(20)30368-9

Atopic Dermatitis

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Br J Dermatol.

Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP, Kamal MA, O'Malley JT, Patel N, Graham NMH, Bansal A

doi: 10.1111/bjd.19460.

Atopic Dermatitis

Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study

J Am Acad Dermatol.

Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz JD, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Staudinger H, Graham NMH, Pirozzi G, Ardeleanu M

doi: 10.1016/j.jaad.2019.07.074.

PsoriasisPsoriatic Arthritis

Secukinumab Demonstrates High Sustained Efficacy and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis through 5 Years of Treatment (SCULPTURE Extension Study)

J Eur Acad Dermatol Venereol.

Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R, Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U

doi: 10.1111/jdv.14878.

Related content

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study

Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study

Secukinumab Demonstrates High Sustained Efficacy and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis through 5 Years of Treatment (SCULPTURE Extension Study)